Inhibitors of KRAS, AKT, and Ezh2 signaling

Description

Mechanistic pathway of recently developed KRAS, AKT, and Ezh2 inhibitors.

Acknowledgements

References

Duan, R., Du, W. & Guo, W. EZH2: a novel target for cancer treatment. J Hematol Oncol 13, 104 (2020). https://doi.org/10.1186/s13045-020-00937-8 Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, David Lawson J, Gunn RJ, Smith CR, Thomas NC, Martinson M, Bergstrom A, Sullivan F, Bouhana K, Winski S, He L, Fernandez-Banet J, Pavlicek A, Haling JR, Rahbaek L, Marx MA, Olson P, Christensen JG. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022 Oct;28(10):2171-2182. doi: 10.1038/s41591-022-02007-7. Epub 2022 Oct 10. PMID: 36216931. Aziz S, Yalan L, Raza MA, Lemin J, Akram HMB, Zhao W. GSK126 an inhibitor of epigenetic regulator EZH2 suppresses cardiac fibrosis by regulating the EZH2-PAX6-CXCL10 pathway. Biochem Cell Biol. 2023 Feb 1;101(1):87-100. doi: 10.1139/bcb-2022-0224. Epub 2022 Dec 5. PMID: 36469862.

Get started with this template for free

Don’t start from scratch.

Create professional scientific illustrations quickly and easily, even without any design expertise

Get started with a huge library of editable icons and templates such as common biological pathways, anatomy, or genetics.
Create figures that effectively communicate your research in half the time using our editable icons.
Use our PDB tool to quickly generate and customize protein structures

Get started now